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Effect of FK 506 in the Prophylaxis of Autoimmurte Glomerulonephritis 
in NZBIWF1 Mice 
G. Carrieri, N. Murase, J. Woo, M. Nalesnik, A. Azzarone, Y. Funakoshi, A.W. Thomson, S. Todo, 
and T.E. Starzl 
THE F I hybrid of New Zealand Black (NZB) and White (NZW) mice spontaneously develops a severe au-
toimmune disease similar to systemic lupus erythematosus 
(SLE) in humans. I The severe glomerulonephritis kills 
50% of these animals at to months of age, and 98% at 1 
year. 
The formation of anti-DNA antibodies and the deposi-
tion of immune complexes of G and I3lcglobulins. plus 
DNA and complement along the capillary walls and the 
mesangia. represent the immunological events that induce 
the glomerulonephritis. 
Several studies have demonstrated the efficacy of immu-
nosuppressive drug therapy in the treatment of the glomer-
ulonephritis in NZB/W FI mice. Cyclophosphamide. aza-
thioprine. and steroids have been reported to be effective 
when initiated at 5 months of age. but to be of little benefit 
when used as a short-term prophylaxis in very young mice 
(1 month) or in mice with advanced renal disease (8 
months).2 Cyclosporine (eyA) has been shown to amelio-
rate the glomerulonephritis in 8-month-old NZBIWF1 •3 In 
this study, FK 506, a novel potent immunosuppressive 
agent with a similar mode of action to CyA, has been used 
as a prophylactic treatment in 6-week-old female NZBI 
WF1 mice. 
MATERIALS AND METHODS 
Animals 
Female NZBIW FI mice were obtained from the Charles River Co 
(Japan) and maintained at the animal facility of the University of 
Pittsburgh. 
FK 506 
FK 506. donated by Fujisawa Pharmaceutical Co (Osaka. Japan). 
was suspended in saline and inoculated subcutaneously. 
CyA 
CyA (Sandoz. Hanover, NJ) was dissolved in intralipid and 
inoculated subcutaneously. 
Experimental Design 
Animals were divided into three groups: group I. mice received no 
treatment; group 2. 6·week-old mice were treated with FK 506 at 
a dose of 1.5 mg/kg per day for 12 weeks; and group 3. 6·week-old 
mice were treated with CyA at a dose of 30 mg/kg per day for 12 
weeks. 
The animals were periodically killed at the ages of 6 weeks. and 
Ii. 8. and 10 months to obtain samples for investigation. 
Anti-DNA Autoantibodies 
Antinuclear antibodies (ANA) were measured using an immuno-
fluorescence method. Principle: DNA antibodies in the test sam· 
pie bind to antigen in the substrate (Crithidia lucidae. which 
contains nONA); excess serum is removed from the substrate by 
washing. Fluorescein-conjugated (FITC) antiserum is added to the 
substrate to which the bound antibodies are attached. After a 
second wash to remove excess conjugate. the substrate is cover-
slipped and viewed for fluorescence reaction with the aid of a 
fluorescent microscope. Only single, well-defined organisms are 
read. 
Con A Lymphocyte Transformation 
Splenic mononuclear cells from individual animals were collected 
and washed after lysis of erythrocytes with Tris-NH4 C1, pH 7.2. 
Cells were washed twice before resuspending in RPMI-I640 
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Table 1. Levels of BUN and Creatinine In Untreated and FK 506- or CyA-treated NZBJWp1 Mice 
Creatinine (mg/dL) 
BUN (mg/dL) 
Data given in mean :!: SO. 
NO = no dill_nee. 
No treatment 
FK506 
CyA 
No treatment 
FK506 
CyA 
6·Week-Old 6·Month-Old 
0.5 :!: 0.1 0.5:!: 0.1 
0.5 ± 0.1 
0.6:!: 0.2 
20.0:!: 2.6 32.5:!: 14.5 
24.8:!: 2.5 
39.0 ± 9.5 
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B·Month·OId 10·MonIh-01d 
0.6:!: 0.1 0.9 :!:0.5 
0.5:!: 0 0.8:!: 0.4 
0.6:!: 0.1 NO 
40.3:!: 39.2 185.5 :!: 194.2 
21.5 :!: 5.0 105 :!: 90.1 
28.5:!: 3.7 NO 
3357 
3358 
Table 2. Number of Anti-DNA Antibody-Positive Animals In Un-
treated and FK 506- or eyA-Treated NZBIWF1 Mice 
No treatment 
FK 506 
CyA 
6-Week-Old 6-Month-Old 8-Month-Old 10-Month-Old 
1/3 (33_3%) 214 (50.0%) 3/4 (75.0%) 3/3 (100%) 
214 (50.0%) 214 (50.0%) 1/3 (25.0%) 
0/4 (0%) 1/4 (25.0%) ND 
NO = no difference. 
(Gibco, Grand Island, NY), supplemented with 10% FBS (Gibco). 
Cells (5 x lOs/well) were incubated with different concentrations 
of Con A for 3 days at 37"C, 5% co2 , in air. One microcurie 
[3H1Tdr was added to each well for 24 hours before cell harvest-
ing, and the degree of cell proliferation was assessed by degree of 
thymidine incorporation. 
Histology 
After sacrifice and autopsy, kidneys were fixed in formalin and 
stained by hematoxylin-eosin. 
RESULTS 
BUN and Creatinine 
No significant difference was observed between the three 
groups (Table I). 
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ANA 
The effect of FK 506 and CyA on anti-DNA antibodies is 
shown in Table 2. In the FK 506 group, the incidence of 
ANA at 8 and 10 months was lower than the other two 
groups; a further reduction in the incidence of ANA 
antibodies was observed in the Cy A group. 
Con A Stimulation 
As shown in Fig I, there was a gradual decrease in the 
lymphocyte-proliferating ability following stimulation with 
Con A from 6- to IO-month-old animals. No difference in 
this response was observed between control animals and 
FK 506-treated animals. 
Histology 
No evidence of glomerulonephritis was observed in the 
kidneys of6-week-old NZBIWF1 mice. At 6 months of age, 
the histology showed the onset of disease in all the groups. 
At 8 and 10 months of age. no differences were observed 
between the different groups (Fig 2) and histological eval-
uation showed enlarged glomeruli. with proliferation of all 
glomerular cellular elements. membranous thickenings of 
the glomerular capillary walls. and focal capillary occlu-
sion with proteinaceous deposit; lymphocyte infiltration 
was also evident. 
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Fig 1. Proliferation of splenic MNC from BALB/c, untreated. and FK 506-treated NZBIWF1 mice at 6 and 10 months of age. following 
stimulation with different concentrations of Con A. 
AUTOIMMUNE GLOMERONEPHRITIS PROPHYLAXIS 
DISCUSSION 
The glomerulonephritis in NZBIW FI mice is reported to be 
related to an immunological event characterized by pro-
duction of anti-DNA antibodies and immune complex 
deposition. Several immunosuppressive agents like CyA. 
cyclophosphamide. and azathioprine have been shown to 
be effective in the treatment of the disease. The data from 
this study show that prophylaxis with FK 506 did not 
prevent or ameliorate the histological changes of the 
glomerulonephritis. However. a lower incidence of ANA 
was observed in the treated animals. Borel et al4 postu-
lated a direct correlation between ANA levels and glomer-
ulonephritis. but Okudaira et al3 reported. in 1987. that the 
beneficial effect of Cy A on the disease was not associated 
with a decreased level of ANA. Our data also showed the 
absence ofa relationship between ANA levels and disease 
evolution. 
In this study. FK 506. a novel potent immunosuppres-
sive agent. which suppresses T-cell immunity. lowered the 
3359 
incidence of AN A antibodies but did not ameliorate histo-
pathological or clinical evidence of the disease. Treatment 
with FK 506 also did not affect the substantially reduced 
lymphocyte response to Con A (seen in NZBIW FI) com-
pared with normal animals. implying that the defective 
T-cell reactivity was not modified by this FK 506 regimen. 
This is consistent with the histological and clinical obser-
vations. Different drug doses and different treatment peri-
ods will be required in future attempts to prevent glomer-
ulonephritis in this particular model of lupus disease. 
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